Dyadic's c1 platform to be used to produce vaccines for humans and animals in africa

Jupiter, fla., nov. 20, 2023 (globe newswire) -- dyadic international, inc. ("dyadic", "we", "us", "our", or the "company") (nasdaq: dyai), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between dyadic's african licensee, rubic one health (“rubic”) and afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using dyadic's c1 protein production platform in south africa for the entire continent.
DYAI Ratings Summary
DYAI Quant Ranking